Press release
Bronchitis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates
To Know in detail about the Bronchitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bronchitis Market Forecast
https://www.delveinsight.com/sample-request/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Bronchitis Market Report:
• The Bronchitis market size is anticipated to grow with a significant CAGR of 4% during the study period (2020-2034)
• In September 2024, CSA Medical, Inc. announced several presentations at the European Respiratory Society (ERS) Congress in Vienna, showcasing new clinical data supporting the use of Metered CryoSpray (MCS) with the RejuvenAir® System for treating Chronic Bronchitis. During the session titled "Cutting-edge concepts in interventional pulmonology: the future is here!", Dr. Christopher Orton, Consultant Respiratory Physician at Royal Brompton Hospital, London, presented research on the potential mechanisms behind bronchial epithelial resurfacing and remodeling using MCS for COPD patients with chronic bronchitis. The study confirmed the clinical effectiveness of Metered CryoSpray in alleviating chronic bronchitis symptoms, as well as a reduction in air trapping and signs of airway remodeling or "rejuvenation."
• In July 2024, CSA Medical finished enrolling participants in its SPRAY-CB trial (NCT03893370) for patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB). This double-blind, sham-controlled trial aims to assess the impact of the Boston-based company's RejuvenAir System on improving patient outcomes.
• The Bronchiolitis Market is expected to experience steady growth, with a strong compound annual growth rate (CAGR) projected from 2024 to 2034. This growth in the 7MM is fueled by the launch of innovative therapies, including IVX-A12 and MK-1654, among others.
• Based on DelveInsight's epidemiology model, the total number of Bronchiolitis cases in the U.S. was around 4 million in 2023. This figure is expected to increase over the forecast period (2024-2034) due to greater awareness, enhanced screening, and advances in genetic testing.
• In 2023, of the etiology-specific Bronchiolitis cases in the U.S., approximately 2 million were caused by Respiratory Syncytial Virus (RSV), while around 1 million were attributed to Non-RSV or other causes.
• In 2023, Japan recorded 677,000 bronchiolitis cases due to Respiratory Syncytial Virus, with an additional 208,000 cases linked to other causes.
• Key Bronchitis Companies: Pfizer, Sanofi, AstraZeneca, Merck, Icosavax, AstraZeneca, Hanlim Pharm. Co., Ltd, Ahn-Gook Pharmaceuticals Co.,Ltd, PharmaKing, Johnson & Johnson, Yuhan Corporation, Korea United Pharm. Inc., Hyundai Pharmaceutical Co., LTD., Ahn-Gook Pharma, Bayer, Wake Forest University, Pfizer, Sanofi, Pharmaxis, EmeraMed, Abgenix, and others
• Key Bronchitis Therapies: ABRYSVO, BEYFORTUS (nirsevimab-alip):, Clesrovimab (MK-1654), IVX-A12, HL301, AGS, N02RS1, levofloxacin, YHD001, KALOMINTM, Acebrophylline, Synatura®, Avelox (Moxifloxacin, BAY12-8039), Oral N-acetycystein (NAC), Moxifloxacin, telithromycin, TPI 1020, Emeramide, ABX-IL8, and others
• The Bronchitis epidemiology based on gender analyzed that in most of the countries, male predominance was observed
• The Bronchitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bronchitis pipeline products will significantly revolutionize the Bronchitis market dynamics.
Bronchitis Overview
An inflammation of the airways entering the lungs is referred to as bronchitis. The person coughs as a result of the inflamed airways (trachea and bronchi) swelling and filling with mucus. The cough may linger a few days to a few weeks. The primary causes of bronchitis can include viruses, smoking, and other irritants.
Get a Free sample for the Bronchitis Market Report:
https://www.delveinsight.com/report-store/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Bronchitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Bronchitis Epidemiology Segmentation:
The Bronchitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Bronchitis
• Prevalent Cases of Bronchitis by severity
• Gender-specific Prevalence of Bronchitis
• Diagnosed Cases of Episodic and Chronic Bronchitis
Download the report to understand which factors are driving Bronchitis epidemiology trends @ Bronchitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Bronchitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchitis market or expected to get launched during the study period. The analysis covers Bronchitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bronchitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Bronchitis Therapies and Key Companies
• ABRYSVO: Pfizer
• BEYFORTUS (nirsevimab-alip): Sanofi/ AstraZeneca
• Clesrovimab (MK-1654): Merck
• IVX-A12: Icosavax/ AstraZeneca
• HL301: Hanlim Pharm. Co., Ltd
• AGS: Ahn-Gook Pharmaceuticals Co.,Ltd
• N02RS1: PharmaKing
• levofloxacin: Johnson & Johnson
• YHD001: Yuhan Corporation
• KALOMINTM: Korea United Pharm. Inc.
• Acebrophylline: Hyundai Pharmaceutical Co., LTD.
• Synatura®: Ahn-Gook Pharma
• Avelox (Moxifloxacin, BAY12-8039): Bayer
• Oral N-acetycystein (NAC): Wake Forest University
• Moxifloxacin: Pfizer
• telithromycin: Sanofi
• TPI 1020: Pharmaxis
• Emeramide: EmeraMed
• ABX-IL8: Abgenix
Discover more about therapies set to grab major Bronchitis market share @ Bronchitis Treatment Market
https://www.delveinsight.com/sample-request/bronchitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of the Bronchitis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bronchitis Companies: Pfizer, Sanofi, AstraZeneca, Merck, Icosavax, AstraZeneca, Hanlim Pharm. Co., Ltd, Ahn-Gook Pharmaceuticals Co.,Ltd, PharmaKing, Johnson & Johnson, Yuhan Corporation, Korea United Pharm. Inc., Hyundai Pharmaceutical Co., LTD., Ahn-Gook Pharma, Bayer, Wake Forest University, Pfizer, Sanofi, Pharmaxis, EmeraMed, Abgenix, and others
• Key Bronchitis Therapies: ABRYSVO, BEYFORTUS (nirsevimab-alip):, Clesrovimab (MK-1654), IVX-A12, HL301, AGS, N02RS1, levofloxacin, YHD001, KALOMINTM, Acebrophylline, Synatura®, Avelox (Moxifloxacin, BAY12-8039), Oral N-acetycystein (NAC), Moxifloxacin, telithromycin, TPI 1020, Emeramide, ABX-IL8, and others
• Bronchitis Therapeutic Assessment: Bronchitis current marketed and Bronchitis emerging therapies
• Bronchitis Market Dynamics: Bronchitis market drivers and Bronchitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bronchitis Unmet Needs, KOL's views, Analyst's views, Bronchitis Market Access and Reimbursement
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bronchitis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates here
News-ID: 4273952 • Views: …
More Releases from DelveInsight Business Research
Limbal Stem Cell Deficiency Market to Surpass USD 2.6 Billion by 2034, Driven by …
In 2023, the Limbal Stem Cell Deficiency (LSCD) market was dominated by the United States, generating nearly USD 1.5 billion in revenue, while Spain represented the smallest market with approximately USD 127 million. This regional distribution is expected to remain consistent throughout the forecast timeline. The US accounted for nearly 103,000 diagnosed LSCD cases, whereas Japan recorded around 37,000 cases, with both countries projected to witness notable growth in patient…
SSc-ILD Market Set to Cross USD 750 Million by 2034, Driven by 10+ Emerging Ther …
The major players operating in the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market include Roche, Prometheus Biosciences, Inc., Merck, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, among others.
DelveInsight's report titled "Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Forecast-2034" delivers a comprehensive analysis of SSc-ILD, covering historical data, projected epidemiology, and evolving market trends across the United States, EU4 (Germany, Spain, Italy, and France),…
Developmental and Epileptic Encephalopathy Treatment Market Poised for Accelerat …
The Developmental and Epileptic Encephalopathy (DEE) treatment market across the seven major markets (7MM) was valued at nearly USD 2.1 billion in 2023 and is expected to register a healthy compound annual growth rate over the forecast period. The United States emerged as the largest contributor, capturing close to 80% of the overall market revenue.
The DEE treatment landscape is undergoing a significant transformation as the limitations of traditional antiepileptic drugs…
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ Therapies and 8+ Co …
DelveInsight's "Polycythemia Vera Pipeline Insight 2025" report delivers an in-depth overview of the Polycythemia Vera pipeline landscape, covering more than 8 companies and 10+ pipeline candidates. The report analyzes both clinical-stage and preclinical assets, offering detailed drug profiles across various stages of development. It also evaluates Polycythemia Vera therapies based on product classification, development stage, route of administration, and molecular category, while additionally spotlighting inactive or discontinued pipeline assets.
Explore the…
More Releases for Bronchitis
Bronchitis Market Key Players, Trends & Forecast to 2034
The Bronchitis Market is expanding steadily as global respiratory infections increase and healthcare systems adopt more effective inhalation therapies, diagnostics, and preventive care strategies. With advancements in chronic bronchitis treatment, growing COPD prevalence, and rising air pollution levels, the market is poised for strong growth through 2034.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/52006
1. What Is Bronchitis? (Keyword Definition)
Bronchitis is an inflammation of the bronchial tubes, which carry air…
Rising Respiratory Disease Incidence Sparks Robust Growth In Bronchitis Treatmen …
The Bronchitis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Bronchitis Treatment Market?
The market for bronchitis treatments has seen robust expansion in the past few years, with projections showing an increase from $5.61 billion in 2024 to…
Acute Bronchitis Treatment Market: An In-Depth Analysis
The global Acute Bronchitis Treatment market was valued at approximately USD 6.3 billion in 2023 and is projected to reach around USD 9.9 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.3% during the forecast period.
Acute Bronchitis Treatment Market Overview
Acute bronchitis is a common respiratory condition characterized by inflammation of the bronchial tubes, leading to symptoms such as coughing and mucus production. The market's growth…
Bronchitis Treatment Market Statistical Forecast, Trade Analysis 2024 - 2031
DataM Intelligence has published a new research report on "Bronchitis Treatment Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF -…
Bronchitis Treatment Market Outlook, Insights, Size 2024-2033
The bronchitis treatment market size has grown strongly in recent years. It will grow from $5.25 billion in 2023 to $5.58 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising air pollution levels, cigarette smoking epidemic, increased respiratory infections, environmental and occupational exposures, lifestyle factors..
The bronchitis treatment market size is expected to see strong…
Bronchitis Market: Study Navigating the Future Growth Outlook
Global Bronchitis Market Report 2019 - Market Size, Share, Price, Trend and Forecast is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Bronchitis Market. Some of the key players profiled in the study are…
